MediWound (MDWD) Given Daily News Impact Rating of 0.11
News headlines about MediWound (NASDAQ:MDWD) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MediWound earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.1155279500827 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s scoring:
- MediWound Ltd. (MDWD) Given a $10.00 Price Target by Oppenheimer Holdings, Inc. Analysts (americanbankingnews.com)
- MediWound Ltd. (MDWD) Given a $9.00 Price Target by SunTrust Banks, Inc. Analysts (americanbankingnews.com)
- MediWound Reports Third Quarter 2017 Financial Results Nasdaq:MDWD (menafn.com)
- Edited Transcript of MDWD earnings conference call or presentation 16-Nov-17 1:30pm GMT (finance.yahoo.com)
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC set a $10.00 target price on shares of MediWound and gave the stock a “buy” rating in a research report on Friday, August 25th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $10.00 price target on shares of MediWound in a report on Monday, September 18th. ValuEngine raised shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Finally, Cowen and Company assumed coverage on shares of MediWound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $9.13.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/20/mediwound-mdwd-given-daily-news-impact-rating-of-0-11.html.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.